KCL-286

KCL-286 (also known as C286) is an orally available small molecule agonist of the retinoic acid receptor beta (RARβ), specifically targeting the RARβ2 isoform. Developed by researchers at King's College London, the compound acts as a neuronal transcription factor that stimulates axonal outgrowth and regeneration in both spinal and sensory nerves. Beyond its regenerative properties, KCL-286 modulates neuroinflammation and alters the composition of the extracellular matrix to create a more permissive environment for repair within the central nervous system. It is primarily being investigated for the treatment of spinal cord injury (SCI) and brachial plexus avulsion. A Phase 1 clinical trial in healthy volunteers demonstrated that the drug is safe and well-tolerated, supporting further development into Phase 2a trials.